论文部分内容阅读
[目的]观察搜风通胶囊联合单硝酸异山梨酯治疗冠状动脉粥样硬化性心脏病心绞痛疗效。[方法]使用随机平行对照方法,将75例住院患者按病志号抽签方法简单随机分为两组。对照组35例单硝酸异山梨酯40mg/次,1次/d,口服;急性发作速效救心丸,4~6丸/次,口服,吸氧。治疗组35例搜风通胶囊4粒/次,3次/d,口服;西药治疗同对照组。连续治疗1个月为1疗程。观测临床症状、心绞痛发作、全血黏度、血浆黏度、红细胞比容、纤维蛋白原、血小板、心电图、不良反应。治疗1疗程,判定疗效。[结果]治疗组显效12例,有效20例,无效3例,总有效率91.43%。对照组显效10例,有效15例,无效10例,总有效率71.43%。治疗组疗效优于对照组(P<0.05)。低切WBV、HCT、FIB两组均有改善(P<0.05),低切WBV、FIB治疗组改善优于对照组(P<0.05,P<0.01),HCT改善两组无明显差异(P>0.05);高切WBV、PV治疗组明显改善(P<0.05),对照组无明显变化(P>0.05),治疗组改善优于对照组(P<0.01,P<0.05);FIB两组均有改善(P<0.01,P<0.05),两组无明显差异(P>0.05);BPC两组均无明显变化(P>0.05)。[结论]搜风通胶囊联合单硝酸异山梨酯治疗冠状动脉粥样硬化性心脏病心绞痛,疗效满意,无严重不良反应,优于单纯单硝酸异山梨酯治疗,值得推广。
[Objective] To observe the curative effect of Sengtong Capsule combined with isosorbide mononitrate on angina pectoris of coronary atherosclerotic heart disease. [Methods] Using randomized parallel control method, 75 inpatients were randomly divided into two groups randomly according to the method of lot drawing of disease symbols. The control group 35 cases of isosorbide mononitrate 40mg / times, 1 times / d, oral; acute attack speed effective heart pill, 4 to 6 pills / time, oral, oxygen. 35 cases of treatment group Feng Feng capsule 4 capsules / time, 3 times / d, oral; western medicine treatment with the control group. Continuous treatment for 1 month for a course of treatment. Observation of clinical symptoms, angina pectoris, whole blood viscosity, plasma viscosity, hematocrit, fibrinogen, platelets, electrocardiogram, adverse reactions. Treatment of a course of treatment to determine the efficacy. [Result] In the treatment group, 12 cases were markedly effective, 20 cases were effective and 3 cases were ineffective. The total effective rate was 91.43%. In the control group, 10 cases were markedly effective, 15 cases were effective and 10 cases were ineffective. The total effective rate was 71.43%. The treatment group was better than the control group (P <0.05). Low-cut WBV, HCT, FIB improved in both groups (P <0.05), low cut WBV, FIB treatment group improved better than the control group (P <0.05, P <0.01), HCT improved no significant difference between the two groups (P> (P <0.05). The improvement of WBV and PV treatment group was significantly improved (P <0.05), but there was no significant difference in control group (P> 0.05). The treatment group improved better than the control group (P <0.01, P < (P <0.01, P <0.05). There was no significant difference between the two groups (P> 0.05). There was no significant difference between the two groups (P> 0.05). [Conclusion] The combination of SOF with isosorbide mononitrate in the treatment of angina pectoris of coronary atherosclerotic heart disease has satisfactory curative effect and no serious side effects. It is better than isosorbide mononitrate alone and is worth promoting.